Last update July 14, 2023
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Entecavir in other languages or writings:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 100 | % |
Molecular weight | 295 | daltons |
Protein Binding | 13 | % |
VD | > 0.7 | l/Kg |
pKa | 12 | - |
Tmax | 0.5 - 1.5 | hours |
T½ | 128 - 149 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Entecavir is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. It is used for the treatment of chronic hepatitis B. Oral administration once daily.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data do not allow predicting the amount of its possible excretion in breast milk. Although the high volume of distribution would prevent it, its low binding to plasma proteins and long elimination half-life would favor its excretion in breast milk.
Pending further published data on this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in case of prematurity.
See below the information of this related product: